Cancer / Immunology
Health Canada Approves Illuccix® for Prostate Cancer Imaging
Illuccix™ [kit for the preparation of gallium (68Ga) gozetotide injection], after radiolabeling with gallium (68Ga), is indicated for use with the po...
October 14, 2022 | News
First patient treated in Clarity's therapeutic prostate cancer trial
Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT0...
October 10, 2022 | News
United Imaging Announces Clinical System Installations at Huntsman Cancer Institute at the University of Utah
United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced that The Center for Quantitative Cancer Imaging ...
September 16, 2022 | News
Merck announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in patients
First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative potential...
September 14, 2022 | News
Merck to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients
Late-breaking data highlight 5-year survival results from Phase II study of the investigational IAP inhibitor xevinapant in the curative setting of unres...
September 08, 2022 | News
Breast Cancer AI Company FathomX Raises SGD$ 2.24 million in Pre-series A Funding
Through this funding, the company will be able to harness the full potential of its digital AI solution to read medical images including mammograms. The fu...
September 02, 2022 | News
Lunit AI Solution for Breast Cancer Detection Wins Commercial Approval in Taiwan
Lunit (KRX: 328130.KQ), a leading medical AI provider, today announced that it received commercial approval in Taiwan for Lunit INSIGHT MMG, the ...
August 26, 2022 | News
Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA)
lacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line...
August 21, 2022 | News
Sirnaomics Commence Treatment of Facial Squamous Cell Skin Cancer In Situ
Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi t...
August 19, 2022 | News
ZAODX World Conference on Early Detection of Cancer was successfully held in Guangzhou, China
In attendance were founders and representatives from over 100 leading companies and institutions involved in cancer screening and early detection from nume...
August 01, 2022 | News
AI-based Cancer Solution Pioneer Lunit Makes Market Debut
Lunit expects to raise approximately KRW 36.4 billion (US$ 28 million). Lunit intends to use the proceeds for R&D of its new AI products and ...
July 22, 2022 | News
New discovery in cancer progression paves way to combat cancer
The life span of a normal healthy cell is determined by telomeres, protective caps at the ends of chromosomes. Each time a cell divides, the telomeres beco...
July 21, 2022 | News
Urgent support needed following the pandemic's effect on cancer screening services
Dry July Foundation is urging Australians to dig even deeper this Dry July to help people affected by cancer. So many Australians could not access vital li...
July 15, 2022 | News
Tampa General Hospital Offers New Treatment Option for Recurrent Brain Cancer to Improve Quality of Life
Tampa General Hospital and USF Health Morsani College of Medicine physicians are the first in Hillsborough County to bri...
July 11, 2022 | News
Most Read
- How Does GLP-1 Work?
- Innovations In Magnetic Resonance Imaging Introduced By United Imaging
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
